Gilead's low-dose, high-impact HIV drug heads to the FDA

A next-generation HIV drug from Gilead Sciences Inc., which could be more effective and have fewer side effects with a lower dosage, will go to federal regulators for a decision on whether it should be approved. The drug — a combination of Gilead's emtricitabine and tenofovir alafenamide, or TAF — is the second so-called F/TAF drug submitted by the Foster City-based company (NASDAQ: GILD) to the Food and Drug Administration. In November, it filed for approval of a once-daily, single-tablet regiment…
Source: bizjournals.com Health Care:Hospitals headlines - Category: Hospital Management Authors: Source Type: news